Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in giant cell arteritis
NL-OMON39663Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tocilizumab in giant cell arteritis (GCA) (4 arms), sponsored by Roche. Primary endpoints: Sustained remission at Week 52, Assessment of giant cell arteritis disease activity and 2 more. Started Jan 2014; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NL-OMON39663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39663.